{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:15:12Z","timestamp":1787508912962,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00192-023-05685-0","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T03:02:32Z","timestamp":1700622152000},"page":"119-126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Injection site number and outcomes of intradetrusor onabotulinumtoxinA for refractory overactive bladder syndrome: a randomized clinical trial"],"prefix":"10.1007","volume":"35","author":[{"given":"Anna","family":"Zdroik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"El Haraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal","family":"Badlani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candace","family":"Parker-Autry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"issue":"6","key":"5685_CR1","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/S0090-4295(01)00986-4","volume":"57","author":"JN Liberman","year":"2001","unstructured":"Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology. 2001;57(6):1044\u201350.","journal-title":"Urology"},{"issue":"7","key":"5685_CR2","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","volume":"108","author":"DE Irwin","year":"2011","unstructured":"Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108(7):1132\u20138.","journal-title":"BJU Int"},{"issue":"3","key":"5685_CR3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/JU.0000000000000309","volume":"202","author":"DJ Lightner","year":"2019","unstructured":"Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment 2019. J Urol. 2019;202(3):558\u201363.","journal-title":"J Urol"},{"key":"5685_CR4","unstructured":"Botox [package insert]. Irvine, CA: Allergan, Inc. 2018."},{"issue":"1","key":"5685_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","volume":"55","author":"A Apostolidis","year":"2009","unstructured":"Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol. 2009;55(1):100\u201319.","journal-title":"Eur Urol"},{"issue":"7","key":"5685_CR6","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00192-007-0548-9","volume":"19","author":"S Kuschel","year":"2008","unstructured":"Kuschel S, Werner M, Schmid DM, Faust E, Schuessler B. Botulinum toxin-a for idiopathic overactivity of the vesical detrusor: a 2-year follow-up. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(7):905\u20139.","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"issue":"4","key":"5685_CR7","first-page":"8","volume":"116","author":"W Lo","year":"2015","unstructured":"Lo W, Lo M. Botulinum toxin-A (boNT\/A) in the treatment of idiopathic detrusor overactivity (IDO) incontinence. A prospective randomized study to compare 20 vs. 10 injection sites. BJU Int. 2015;116(4):8.","journal-title":"BJU Int"},{"issue":"3","key":"5685_CR8","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.juro.2006.10.050","volume":"177","author":"BL Cohen","year":"2007","unstructured":"Cohen BL, Rivera R, Barboglio P, Gousse A. Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection. J Urol. 2007;177(3):1006\u201310 (discussion 1010).","journal-title":"J Urol"},{"issue":"8","key":"5685_CR9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/SPV.0000000000001199","volume":"28","author":"ES Chang","year":"2022","unstructured":"Chang ES, Ringel N, Woodburn KL, et al. Postprocedural pain associated with 5 versus 20 intradetrusor injections of onabotulinumtoxinA for treatment of overactive bladder: a multicenter randomized clinical trial. Urogynecology (Phila). 2022;28(8):518\u201325.","journal-title":"Urogynecology (Phila)"},{"issue":"3","key":"5685_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/nau.22559","volume":"34","author":"KS Coyne","year":"2015","unstructured":"Coyne KS, Thompson CL, Lai JS, Sexton CC. An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF. Neurourol Urodyn. 2015;34(3):255\u201363.","journal-title":"Neurourol Urodyn"},{"issue":"7","key":"5685_CR11","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1089\/end.2005.19.880","volume":"19","author":"CP Smith","year":"2005","unstructured":"Smith CP, Chancellor MB. Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection. J Endourol. 2005;19(7):880\u20132.","journal-title":"J Endourol"},{"issue":"1","key":"5685_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0304-3959(86)90228-9","volume":"27","author":"MP Jensen","year":"1986","unstructured":"Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain. 1986;27(1):117\u201326.","journal-title":"Pain"},{"issue":"1","key":"5685_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jmpt.2003.11.003","volume":"27","author":"H Hurst","year":"2004","unstructured":"Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther. 2004;27(1):26\u201335.","journal-title":"J Manipulative Physiol Ther"},{"issue":"1","key":"5685_CR14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/nau.25107","volume":"42","author":"AM DiCarlo-Meacham","year":"2023","unstructured":"DiCarlo-Meacham AM, Dengler KL, Welch EK, et al. Reduced versus standard intradetrusor OnabotulinumtoxinA injections for treatment of overactive bladder. Neurourol Urodyn. 2023;42(1):366\u201374.","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"5685_CR15","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","volume":"189","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186\u201393.","journal-title":"J Urol"},{"issue":"1","key":"5685_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/nau.25061","volume":"42","author":"N Faure Walker","year":"2023","unstructured":"Faure Walker N, Macpherson F, Tasleem A, Rampal T. Interventions to improve tolerability of local anesthetic intradetrusor botulinum toxin injections: a systematic review. Neurourol Urodyn. 2023;42(1):23\u201332.","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"5685_CR17","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","volume":"184","author":"R Dmochowski","year":"2010","unstructured":"Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416\u201322.","journal-title":"J Urol"},{"issue":"2","key":"5685_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.eururo.2007.10.013","volume":"53","author":"G Karsenty","year":"2008","unstructured":"Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin a (botox) intradetrusor injections in adults with neurogenic detrusor overactivity\/neurogenic overactive bladder: a systematic literature review. Eur Urol. 2008;53(2):275\u201387.","journal-title":"Eur Urol"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-023-05685-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-023-05685-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-023-05685-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T12:44:53Z","timestamp":1730551493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-023-05685-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["5685"],"URL":"https:\/\/doi.org\/10.1007\/s00192-023-05685-0","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]},"assertion":[{"value":"26 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Catherine A. Matthews is a grant recipient and consultant for Boston Scientific Corporation and Coloplast and is an expert witness for defense for Johnson & Johnson. The other authors did not report any potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}